Oral Tablet -> Finasteril
Pharmaceutical Name: Finasteril
Chemical Name: Finasteride
Unit Available:100 Tabs
Each tablet contain: 1 mg.
Finasteride is an inhibitor of 5a-reductase, which is the enzyme responsible for converting testosterone into DHT (dihydrotestosterone).This drug can efficiently reduce the serum concentration of DHT, thereby minimizing the unwanted and rogenic effects that result from its presence. The effect of this drug is quite rapid, suppressing serum DHT concentrations as much as 65% within 24 hours after taking a single lmg tablet. Medically, this drug is used to treat benign prostate hyperplasia (prostate enlargement) and androgenetic alopecia (male pattern hair loss). It is also being investigated as a potential treatment for hirsutism, which describes male patterned hair growth on the face or body of a woman. Nlale athletes and bodybuilders are interested in finasteride for its ability to reduce the androgenic side effects associated with the use of testosterone and certain derivatives.
Finasteride is a specific inhibitor of the Type-ll 5a reductase enzyme. There are actually two isozymes of reductase In the human body, labeled as Type-l and Type-ll.Type-l 5a-reductase is predominantly found in the liver and sebaceous glands of the skin. Type-ll 5a-reductase is primarily found in the prostate and hair foIlicles.The Type-ll enzyme is responsible for about 2/3rd of the circulating DHT, while the Type-l enzyme produces the remaining l/3rd. As an inhibitor of Type-ll reductase only, finasterlde has a more pronounced effect with regard to preventing hair loss, but is somewhat less effective at mitigating oily skin and acne. Since hair loss is the primary worry among most male steroid users who use reductase inhibitors, finasteride remains a popular ancillary drug in spite of its inability to block DHT conversion in all tissues.
Finasteride is considered a highly specific drug, as it has little spillover effect on the other hormones in the body. lt has no affinity for the androgen or estrogen receptors, and therefore does not exhibit any androgenic, anti-androgenic, estrogenic, or anti-estrogenic properties. It has no appreciable impact on circulating levels of cortisol, thyroid-stimulating hormone, or thyroxine, nor does it appear to alter HDL/LDL cholesterol levels. Changes in luteinizing hormone (LH) or follicle-stimulating hormone (FSH) are also not notable, and it is not shown to have a significant effect on the hypothalamic-pituitary testicular axis. Finasteride has been shown to increase the circulating levels of testosterone by roughly 15% however, since a greater amount of the androgen is being left unaltered by the reductase enzyme.
Finasteride is a synthetic 4-azasteroid. it has the chemical designation 4-azaandrost-1-ene-1 7-carb0xamide,N-(1 1-dimethylethyl)-3-oxo-,(5,1 7,)
Reductase inhibitors cannot completely protect against androgenic side effects such as steroid-induced hair loss, oily skin, and acne. Reductase inhibitors lessen these side effects by reducing, not eliminating, the level of androgenic activity in the skin and scalp. Androgenic and anabolic effects are both mediated by the same receptor, and there is no way presently known to completely separate these two properties. Dihydrotestosterone is also not unique in its ability to facilitate androgenetic alopecia (male pattern hair loss). DHT inhibition,therefore, does not offer complete protection against this side effect.
Reductase inhibitors are only applicable with testosterone, methyltestosterone, and fluoxymesterone. These three drugs are converted to stronger "dihydro" derivatives by the reductase enzyme. Nandrolone and some of its derivatives become weaker upon interaction with this enzyme, as their "dihydro" metabolites bind the androgen receptor very poorly. Reductase inhibition may intensify their androgenic side effects. Nlethandrostenolone and boldenone undergo conversion to stronger 5-alpha reduced metabolites, but at such small levels that reductase inhibitors have little effect on their androgenicity. l\/lost other synthetic anabolic steroids are unaffected by the reductase enzyme and reductase inhibitors.
Adverse reactions commonly associated with the short-term (1 year) use of finasteride include impotence (8.1%), decreased libido (6.4%), decreased ejaculate volume (3.7%), ejaculation disorder (0.8%), gynecomastia (0.5%), breast tenderness (0.4%), and rash (0.5%).
Systematic name : N-(1,1-dimethylethyl)-3-oxo-4-azaandrost-1-ene-17-carboxamide